Julia Aijun Wang Sells 397 Shares of BeiGene, Ltd. (NASDAQ:BGNE) Stock

BeiGene, Ltd. (NASDAQ:BGNEGet Free Report) CFO Julia Aijun Wang sold 397 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $167.08, for a total value of $66,330.76. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

BeiGene Stock Up 1.7 %

BGNE stock traded up $2.84 during mid-day trading on Monday, hitting $167.86. 183,149 shares of the company were exchanged, compared to its average volume of 312,296. The company has a market capitalization of $16.02 billion, a PE ratio of -19.67 and a beta of 0.62. The firm has a fifty day simple moving average of $162.46 and a 200 day simple moving average of $178.49. BeiGene, Ltd. has a twelve month low of $132.95 and a twelve month high of $272.49. The company has a current ratio of 2.32, a quick ratio of 2.09 and a debt-to-equity ratio of 0.06.

BeiGene (NASDAQ:BGNEGet Free Report) last announced its earnings results on Monday, February 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.61) by $0.08. The business had revenue of $634.40 million during the quarter, compared to analysts’ expectations of $632.52 million. BeiGene had a negative net margin of 35.86% and a negative return on equity of 23.12%. The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. During the same quarter last year, the company posted ($4.29) EPS. On average, research analysts forecast that BeiGene, Ltd. will post -7.53 earnings per share for the current fiscal year.

Institutional Trading of BeiGene

Hedge funds and other institutional investors have recently made changes to their positions in the business. Goldman Sachs Group Inc. raised its stake in BeiGene by 175.2% in the fourth quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock valued at $38,658,000 after purchasing an additional 136,458 shares in the last quarter. Virtu Financial LLC raised its stake in BeiGene by 94.2% during the fourth quarter. Virtu Financial LLC now owns 5,319 shares of the company’s stock worth $959,000 after acquiring an additional 2,580 shares in the last quarter. Exome Asset Management LLC acquired a new position in BeiGene during the fourth quarter worth about $2,309,000. Virtus ETF Advisers LLC lifted its holdings in shares of BeiGene by 19.2% during the fourth quarter. Virtus ETF Advisers LLC now owns 1,739 shares of the company’s stock worth $314,000 after purchasing an additional 280 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its stake in BeiGene by 9.1% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,908,189 shares of the company’s stock worth $344,162,000 after buying an additional 158,624 shares during the last quarter. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $185.00 target price on shares of BeiGene in a research note on Tuesday, February 6th. StockNews.com raised BeiGene from a “sell” rating to a “hold” rating in a research report on Thursday, November 9th. Finally, Guggenheim cut their price target on BeiGene from $350.00 to $345.00 and set a “buy” rating on the stock in a research report on Tuesday, February 27th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $260.78.

Get Our Latest Stock Analysis on BeiGene

BeiGene Company Profile

(Get Free Report)

BeiGene, Ltd., a biotechnology company, develops and commercializes oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; Tislelizumab to treat various solid tumor and blood cancers; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumor malignancies; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Further Reading

Insider Buying and Selling by Quarter for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.